Cyclodextrin News

August 12, 2021 Drug delivery / Pharma applications

Marinus Pharmaceuticals and Orion Corporation agree on Commercialization of SBECD-enabled Ganaxolone

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that

January 14, 2021 Drug delivery / Pharma applications

Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder (CDD)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders,

December 11, 2020 Drug delivery / Pharma applications

Marinus Pharmaceuticals Provides SBECD-enabled Ganaxolone Clinical Data

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced it

September 17, 2020 Pharma applications

Marinus Awarded BARDA Contract to Develop SBECD-enabled Ganaxolone for Treatment of Refractory Status Epilepticus

Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced it has

December 19, 2019 Drug delivery / Pharma applications

Marinus Data from SBECD-enabled Ganaxolone Phase 2 Trial in Refractory Status Epilepticus

Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric

October 3, 2019 Pharma applications

Positive Results With SBECD-enabled Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders,